NVAX - NovavaxAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $129.98 | Open | $129.69 |
| Volume | 3.31M | Market Cap | 8.275B |
| Yield | Last Dividend |
| 4 more Covid-19 vaccines in different st... | 01/17/21 |
| New Delhi, January 17 Apart from Covishield, the Serum Institute of India (SII) is working on four more vaccines against the novel coronavirus, accord... | |
| Faces of the News: January 17, 2021 | 01/16/21 |
| Carlito Galvez Jr. As the country's vaccine czar and chief implementer of the National Task Force Against COVID-19, Carlito Galvez Jr. has been helpin... | |
| Why Novavax Could Become a Latecomer Lea... | 01/16/21 |
| This small biotech could be like the tortoise in Aesop's famous fable. | |
| FXNEWS24 |Novavax (NVAX) Dips Extra Than... | 01/16/21 |
| Novavax (NVAX) Dips Extra Than Broader Markets: What You Ought to Know | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News | |
| Novavax COVID-19 vaccine trial opens at ... | 01/16/21 |
| SAN ANTONIO, Jan. 16, 2021 /PRNewswire-PRWeb/ ??? San Antonians will have the opportunity to participate in the fifth international COVID-19 vaccine c... | |
| Europe and Canada are facing temporary h... | 01/15/21 |
| Summary List Placement European countries and Canada will receive fewer doses of Pfizer's coronavirus vaccine than planned in the weeks ahead, an unex... | |
| Novavax Hires Regulatory Expert As Coron... | 01/15/21 |
| Novavax, Inc. (NASDAQ: NVAX ) is beefing up its executive team as it prepares to release results of its late-stage coronavirus vaccine study and file ... | |
| Is Novavax's Growth Story Over? | 01/15/21 |
| The next few weeks could be critical for the biotech's coronavirus vaccine prospects. | |
| Before Summer 36 Percent of Bulgarians W... | 01/15/21 |
| Nearly 36% of the population of Bulgaria may be vaccinated in the first six months of this year, BGNES learnt from the press office of the Ministry of... | |
| Vaccine ETFs outperform Nasdaq and S&P50... | 01/14/21 |
| Covid-19, Covid-19 vaccine, exchange traded fund (ETF), Biotechnology stocks, Moderna, Pfizer Inc, AstraZenaca, BioNTech, Sinopharm, CanSinoBiologics ... | |
| Vaccine Stocks In The Coming Vaccine Glu... | 01/14/21 |
| Vaccine Stocks In The Coming Vaccine Glut Submitted by Thomas Kirchner of Camelot Portfolios Production capacity is built for billions of doses of vac... | |
| India's Serum Institute expects WHO emer... | 01/14/21 |
| The Serum Institute of India expects WHO emergency-use authorization soon for the Oxford University/AstraZeneca coronavirus vaccine, which it is produ... | |
| Serum Institute to stockpile Novavax vac... | 01/14/21 |
| Upwards of 40-50 million doses per month is what we are trying to stockpile starting from April, he said. | |
| LGUs may have COVID vaccine deals with M... | 01/13/21 |
| MANILA, Philippines --- Apart from British drugmaker AstraZeneca, local government units (LGUs) may also enter into a tripartite agreement to secure v... | |
| 50% vaccine efficiency not enough, Zubir... | 01/13/21 |
| MANILA, Philippines --- Senate Majority Leader Juan Miguel Zubiri underscored on Wednesday that COVID-19 vaccines with only 50 percent efficacy rate w... | |
| WHO asks SII for Covishield trial data | 01/13/21 |
| MUMBAI: The World Health Organisation has asked Serum Institute of India to submit its data from clinical trials of the AstraZeneca/Oxford vaccine con... | |
| Baxter Germany to start production of Bi... | 01/13/21 |
| Baxter plans to start production of the COVID-19 vaccine by BioNTech and Pfizer in Germany in late February or early March, Juergen Fleischer, personn... | |
| Australia's COVID-19 vaccines: Pfizer, A... | 01/12/21 |
| Australians will begin receiving the coronavirus vaccine within weeks. | |
| Top bosses at drugs firm Novavax pocket ... | 01/12/21 |
| Novavax chief executive Stanley Erck and three of his colleagues offloaded the stock in a series of transactions since the start of 2020, capitalising... | |
| Baxter (BAX) Inks Sterile Manufacturing ... | 01/12/21 |
| Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. ... | |
| Novavax taps Baxter for commercial produ... | 01/12/21 |
| Novavax tapped Baxter BioPharma Solutions to support commercial-scale vaccine manufacturing at its facility in Halle, Germany. Once manufacturing work... | |
| S. Korea May Soon Seal Deal to Purchase ... | 01/12/21 |
| No summary available. | |
| S. Korea nears deal to buy Novavax COVID... | 01/12/21 |
| South Korea is close to striking a deal to purchase COVID-19 vaccines for 10 million people from US drugmaker Novavax, according to informed sources T... | |
| S. Korea nears deal to buy Novavax COVID... | 01/12/21 |
| SEOUL, Jan. 12 (Yonhap) -- South Korea is close to striking a deal to purchase COVID-19 va??? | |
| Why Novavax Fell by Over 4% Today | The ... | 01/11/21 |
| Investors seem perturbed by some reporting about top managers' recent financial moves. | |
| Why Novavax Stock Is Bound for Massive G... | 01/11/21 |
| Novavax lost the race to be first with a Covid-19 vaccine, but NVX-CoV2373 is nearing approval. It will boost NVAX stock in 2021. | |
| Novavax bosses cash out $46 million with... | 01/11/21 |
| Worth only US$250 million until about a year ago, but news of experimental vaccine drove valuation up to as much as US$11 billion | |
| Buy rating | 12/14/20 |
| Jefferies initiates coverage with Buy rating and announces Price Target of $200.00 | |
| Buy rating | 11/17/20 |
| HC Wainwright & Co. maintains Buy rating and lowers Price Target from $290.00 to $207.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Pennies | Mmkt0652 | 87.00 % | Subscribe |
| Trading Systems | Trading Systems | 84.00 % | Subscribe |
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| Tech Trades | Tech Trades | 81.00 % | Follow |
| Option Superstars | James Catzen | 75.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
